Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk for Gout – a Comparison Among Canagliflozin, Dapagliflozin and Empagliflozin

Oct-20

AUTHORS : Dr Tuhina Neogi, Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, 650 Albany St, X Bldg, Ste 200, Boston, MA 02118 – Email: tneogi@bu.edu – Profile: https://www.bumc.bu.edu/busm/profile/tuhina-neogi/ – Cannot find contact details for Ana Beatriz Vargas-Santos

JOURNAL : Arthritis & Rheumatology

REFERENCE: 72(S10)

DOI : 10.1002/art.41538

Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk for Gout – a Comparison Among Canagliflozin, Dapagliflozin and Empagliflozin

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study